Flutter Over Debut Of Glenmark's Favipiravir For COVID-19 In India

Poised For Scale-Up Using In-House Capabilities

Glenmark has received the go-ahead in India for its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process. While the firm says trial findings are in line with global data, with patients showing clinical improvements within the first seven days, social media is abuzz, with some physicians seeking greater clarity.  

Coronavirus COVID-19 medical test vaccine research and development concept. Scientist in laboratory study and analyze scientific sample of Coronavirus antibody to produce drug treatment for COVID-19.
Favipiravir Gets India Green Light After Accelerated Approval • Source: Shutterstock

Glenmark Pharmaceuticals Ltd. appears to have stolen a march over its peers after it received regulatory clearance in India for its version of favipiravir, the antiviral currently being evaluated as part of treatment options for COVID-19 in several countries including Japan.

Glenmark’s product, to be sold as FabiFlu, has received emergency use authorization in India for the treatment of mild to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia